	US 12,441,805 B2
	Antagonistic anti-TNFR2 antibodies
Björn Frendéus, Lund (SE); Ingrid Teige, Lund (SE); Linda Mårtensson, Bjärred (SE); Petra Holmkvist, Kävlinge (SE); and Monika Semmrich, Malmö (SE)
Assigned to BIOINVENT INTERNATIONAL AB, Lund (SE)
Appl. No. 17/290,352
Filed by BIOINVENT INTERNATIONAL AB, Lund (SE)
PCT Filed Nov. 1, 2019, PCT No. PCT/EP2019/080004 § 371(c)(1), (2) Date Apr. 30, 2021, PCT Pub. No. WO2020/089474, PCT Pub. Date May 7, 2020.
Claims priority of application No. 18203993 (EP), filed on Nov. 1, 2018.
Prior Publication US 2022/0073634 A1, Mar. 10, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2878 (2013.01) [A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 16/283 (2013.01); C07K 2317/30 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01)]

29 Claims

1. An antagonistic antibody molecule that specifically binds to TNFR2 on a target cell and thereby blocks TNF-α binding to TNFR2 and blocks TNFR2 signaling, and wherein the antibody molecule also binds to an Fcγ receptor via its Fc region, wherein the antagonistic antibody molecule comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 and VL-CDR3 of (a) SEQ ID NOS: 1, 2, 3, 4, 5 and 6, (b) SEQ ID NOS: 9, 10, 11, 12, 13 and 14, or (c) SEQ ID NOS: 17, 18, 19, 20, 21 and 22.